8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 3, 2026

Stoke Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-38938	47-1144582
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

45 Wiggins Ave

Bedford, Massachusetts

01730

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 430-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	STOK	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 3, 2026, Stoke Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders, and the following proposals were adopted:

Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term, which will expire upon the earlier of the 2029 annual meeting of stockholders or until such time as their respective successors have been duly elected and qualified or their earlier resignation or removal:


Nominees	Shares For	Shares Withheld	Broker Non-Votes
G. Clare Kahn, Ph.D.	49,722,339	308,644	5,143,930
Adrian Krainer, Ph.D.	36,531,612	13,499,371	5,143,930
Julie Anne Smith	43,500,649	6,530,334	5,143,930

2.	Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:


Shares For	Shares Against	Shares Withheld/Abstaining
55,121,163	2,036	51,714

3.	Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 22, 2026:


Shares For	Shares Against	Shares Withheld/Abstaining	Broker Non-Votes
36,436,275	13,565,293	29,415	5,143,930

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 4, 2026


STOKE THERAPEUTICS, INC.

By:		/s/ Thomas E. Leggett
		Thomas E. Leggett
		Chief Financial Officer

SEC Form 8-K filed by Stoke Therapeutics Inc.